Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020
Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.
Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.
KEY BENEFITS:
Global Stem cell UCB market by storage
Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.
KEY BENEFITS:
- This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell market
- Detailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decision
- Value chain analysis, Porter’s five forces, top investment pockets are analysed and presented in detail in the report
- Intelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisions
- SWOT analysis and strategic developments included in the report for Key players: Advanced Cell Technology, Inc. (USA), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.
Global Stem cell UCB market by storage
- Public cord blood banks
- Private cord blood banks
- Public Vs. Private UCB banks
- Cancer/ Oncology diseases
- Acute Leukemia
- Chronic Leukemia
- High Risk Solid Tumors
- Myelodysplastic Syndrome
- Blood diseases
- Aplastic Anemia
- Beta Thalassemia
- Sickle Cell disease
- Immune Disorders
- Leukocyte Adhesion Deficiency
- Hystiocytic Disorders
- Wiskott-Aldrich
- Metabolic Disorders
- Krabbe Disease
- Hurler Syndrome
- Sanfilippo Syndrome
- Other diseases
- Osteopetrosis
- Hemophagoyticlymphohistiocytosis
- Stem Cell Transplant
- Autologous transplant
- Allogenic transplant
- Transplant Medicine
- Regenerative Medicine
- Others
- Cord Blood Banking
- Blood Transfusion
- Cell Based Genetics
- UCB market in North America
- UCB market in Europe
- UCB market in Asia-pacific
- UCB market in ROW
- Therapeutics service companies
- Private and government research institutes
- Academic Institutes
- Research based pharmaceutical companies
- Public and Private cord blood banks
CHAPTER 1 INTRODUCTION
1.1 Key objectives
1.2 Key benefits
1.3 Key deliverables
1.4 Key audiences
1.5 Research methodology
1.5.1 Secondary research
1.5.2 Primary research
1.5.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Umbilical cord blood stem cell market by Geography , 2012-2020, $million
CHAPTER 3 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEW
3.1 Market Description
3.2 Market definition and Scope
3.3 Awareness programs for cord blood donation
3.4 Key findings
3.4.1 Top ten factors impacting UCB stem cell market
3.4.1.1 Minimal invasive techniques of collection and transferring
3.4.1.2 Efficient extraction of cord blood
3.4.1.3 Storage service for maintaining viability
3.4.1.4 Government regulation and intervention
3.4.1.5 Ethical issues in storage and application
3.4.1.6 Cost of treatment
3.4.1.7 Availability of treatment and sample
3.4.1.8 Positive engraftment of tissue
3.4.1.9 Efficient transferring during treatment
3.4.1.10 Reimbursement and insurance issues in storage
3.4.2 Top winning strategies
3.4.3 Top Investment pockets
3.4.3.1 UCB stem cell market - by Application
3.4.3.2 UCB market- by Therapeutics
3.4.3.3 UCB market- by Storage service
3.5 Advantages of umbilical cord blood stem cells over peripheral blood stem cells
3.6 Key advantages of UCB stem cells.
3.6.1 Prompt availability
3.6.2 Ease of collection
3.6.3 More tolerance for graft failure
3.6.4 Reduce risk of Graft vs. host disease (GvHD)
3.6.5 Decreased transmission of viral disease infection
3.7 Regulatory issues, legislations and authorities Reimbursement Issues
3.7.1 Regulatory issues of UCB stem cells storage and application (U.S.)
3.7.1.1 American Academy of Pediatrics (AAP)
3.7.1.2 American society for Blood and Marrow Transplantation (ASBMT)
3.7.2 Regulatory issues concenringUCB stem cells storage and application in European countries
3.7.3 Reimbursement issues
3.8 Ethical issues of stem cell therapies and cord blood banking
3.8.1 Ethical issues regarding cord blood banking
3.8.2 Ethical issues in cord blood stem cell therapies
3.9 Umbilical cord blood stem cell collection process
3.10 UCB Stem cells Storage and collection Outsourcing
3.10.1 Stem cell storage and collection outsourcing
3.10.1.1 Criteria for outsourcing of cord blood storage
3.11 Key patents and analysis of Novel Patents
3.12 Clinical trials in UCB stem cell market
3.12.1 Phase 2 Study of stem cell Educator Therapy in Type 1 Diabetes
3.12.2 Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children
3.12.3 Longitudinal Study of Immune Mediated Disorders After AllogenicHematopoietic Cell Transplantation (HCT)
3.12.4 Evaluation of Hematopoietic and Immunologic Reconstitution after a Reduced-intensity Conditioning Regimen
3.12.5 Umbilical Cord Blood Transplant for Congenital Pediatrics Disorders
3.13 Value chain analysis of UCB stem cell market
3.14 Porter’s five forces analysis for cord blood stem cell market
3.14.1 Higher bargaining power of suppliers for getting competitive advantage
3.14.2 Lower bargaining power of buyers in terms of treatment
3.14.3 Higher degree of competition
3.14.4 Threats of new entrants increases due to novel therapies
3.14.5 Increased threats fromconventional therapies and banking substitutes
3.15 Market Dynamics of UCB stem cell market
3.15.1 Market Drivers
3.15.1.1 Minimal invasive methods
3.15.1.2 Treatment on chronic diseases
3.15.1.3 Cost effective therapy and storage
3.15.1.4 Easy extraction methods
3.15.1.5 Intact genetic structure
3.15.2 Market Restraints
3.15.2.1 Government regulations and intervention
3.15.2.2 Legal and ethical issues during collection
3.15.2.3 Availability of right type of donor
3.15.2.4 Higher cost of therapies
3.15.3 Market Opportunities
3.15.3.1 Advancement in therapeutic application
3.15.3.2 Rising funds for public storage
3.15.3.3 Increase in cost effectiveness to increase APAC market presence
CHAPTER 4 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICE
4.1 Difference between Public vs. Private UCB banks
4.1.1 Umbilical cord blood stem cell storage service market ,2012-2020, $million
4.2 Market Drivers
4.2.1 Lower cost structure
4.2.2 Immediate availability
4.2.3 Government Intervention
4.2.4 Decrease transplant complications
4.3 Market Restraints
4.3.1 Long term storage
4.3.2 Lower volume of blood
4.3.3 Operational Issues
4.3.4 Legal & Ethical Issues
4.4 Market Opportunities
4.4.1 Additional fund collection
4.4.2 Technological adoptions
4.4.3 Insurance as USP
4.4.4 Lowering healthcare costs
4.5 Public cord blood banks
4.5.1 Cost structure of public cord blood banking:
4.5.2 UCB public storage bank service market , 2012-2020, $million
4.6 Private cord blood banks
4.6.1 UCB private storage bank service market ,2012-2020, $million
CHAPTER 5 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICS
5.1 Umbilical cord blood stem cell therapeutics market , 2012-2020, $million
5.2 Market Drivers
5.2.1 Fast recovery
5.2.2 Efficient transferring of stem cells
5.2.3 Minimum invasive technique
5.2.4 Target specific
5.3 Market Restraints
5.3.1 Higher cost of treatment
5.3.2 Scarcity of donor
5.3.3 Rejection in allogenictransplantation
5.3.4 Difficulty in donor matching
5.4 Opportunities
5.4.1 Increasing flexibility
5.4.2 Improved donor policy
5.4.3 Risk management
5.5 Cancer/ Oncology diseases
5.5.1 UCB stem cell cancer therapeutics geography market , 2012-2020, $million
5.5.2 UCB stem cell cancer therapeutics market , 2012-2020, $million
5.5.3 Acute Leukemia
5.5.4 UCB stem cell Acute leukemia therapeutics market , 2012-2020,$million
5.5.5 Chronic Leukemia
5.5.6 GLOBAL UCB stem cell Chronic leukemia therapeutics market , 2012-2020, $million
5.5.7 High risk solid tumours
5.5.8 Global UCB stem cell high risk solid tumor therapeutics market , 2012-2020, $million
5.5.9 Myelodysplastic syndrome
5.5.10 Global UCB stem cell Myleodysplastic syndrome (MDS) therapeutics market , 2012-2020,$million
5.5.11 Others(chronic myelomonocyticleukemia (CMML))
5.5.12 UCB stem cell other disease therapeutics geography market , 2012-2020, $million
5.6 Diabetes
5.6.1 Global UCB stem cell diabetes therapeutics market , 2012-2020, $million
5.6.2 Global UCB stem cell diabetes therapeutics geography market , 2012-2020, $million
5.6.3 Type 1 diabetes
5.6.4 Global UCB stem cell type I diabetes therapeutics geography market, 2012-2020, $million
5.6.5 Type 2 diabetes
5.6.6 UCB stem cell Type II diabetes therapeutics geography market , 2012-2020, $million
5.6.7 Others(Gestational Diabetes Mellitus(GDM))
5.6.8 UCB stem cell Gestational Diabetes Mellitus(GDM) therapeutics geography market , 2012-2020, $million
5.7 Blood diseases
5.7.1 UCB stem cell blood diseases therapeutics market , 2012-2020, $million
5.7.2 UCB stem cell blood diseases therapeutics geography market, 2012-2020, $million
5.7.3 Aplastic Anemia
5.7.4 Global UCB stem cell Aplastic anemia therapeutics geography market 2012-2020, $million
5.7.5 Beta Thalassemia
5.7.6 Global UCB stem cell Thalassemia therapeutics geography market , 2012-2020, $million
5.7.7 Sickle Cell disease
5.7.8 Global UCB stem cell Sickle cell disease therapeutics geography market 2012-2020, $million
5.7.9 Others (Iron deficiency anemia)
5.7.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million
5.8 Immune Disorders
5.8.1 Global UCB stem cell immune disorders therapeutics market , 2012-2020, $million
5.8.2 Global UCB stem cell immune disorders therapeutics geography market , 2012-2020, $million
5.8.3 Leukocyte Adhesion Deficiency
5.8.4 Global UCB stem cell Leukocyte Adhesion deficiency therapeutics geography market , 2012-2020, $million
5.8.5 Hystiocytic disorders
5.8.6 Global UCB stem cell Hystiocytic disorders therapeutics geography market 2012-2020, $million
5.8.7 Wiskott-Aldrich
5.8.8 Global UCB stem cell Wiskott-Aldrich therapeutics geography market 2012-2020, $million
5.8.9 Others(Inflammatory Bowel Disease (IBD) and Multiple Sclerosis(MS))
5.8.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million
5.9 Metabolic Disorders
5.9.1 Global UCB stem cell metabolic disorders therapeutics market , 2012-2020, $million
5.9.2 Global UCB stem cell metabolic disorders therapeutics geography market , 2012-2020, $million
5.9.3 Krabbe Disease
5.9.4 Global UCB stem cell Krabbe disease therapeutics geography market , 2012-2020, $million
5.9.5 Hurler Syndrome
5.9.6 Global UCB stem cell Hurler syndrome therapeutics geography market , 2012-2020, $million
5.9.7 Sanfilippo Syndrome
5.9.8 Global UCB stem cell Sanfilippo Syndrome therapeutics geography market , 2012-2020, $million
5.9.9 Others (Fabry disease)
5.9.10 Global UCB stem cell Fabry disease therapeutics geography market , 2012-2020, $million
5.10 Other diseases
5.10.1 Global UCB stem cell other disease therapeutics market 2012-2020, $million
5.10.2 Osteopetrosis
5.10.3 Global UCB stem cell Osteopetrosis disease therapeutics geography market, 2012-2020, $million
5.10.4 Hemophagoyticlymphohistiocytosis (HLH)
5.10.5 Global UCB stem cell Hemophagoytic lymphohistiocytosis therapeutics geography market , 2012-2020, $million
CHAPTER 6 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATION
6.1 Umbilical cord blood stem cell application market , 2012-2020, $million
6.2 Drivers of UCB stem cell application market
6.2.1 Auto-repair process
6.2.2 Pre-surgery management
6.2.3 Disease information
6.2.4 Positive engraftment
6.3 Restraints of UCB stem cell application market
6.3.1 Higher cost of treatment
6.3.2 Genetic variation
6.3.3 Donor Matching
6.3.4 Ethical problem
6.4 Opportunity of UCB stem cell application market
6.4.1 Cost effective regenerative medicines
6.4.2 Wound management therapies
6.4.3 Growing research institute
6.5 Stem Cell Transplant
6.5.1 Global UCB stem cell transplant application market , 2012-2020, $million
6.5.2 Autologous transplant
6.5.3 Global UCB stem cell autologous transplant applicationgeogrpahy market 2012-2020, $million
6.5.4 Allogenictransplant
6.5.5 Global UCB stem cell allogenic transplant application geography market , 2012-2020, $million
6.6 Transplant Medicine
6.6.1 Global UCB stem cell transplant medicine application geography market , 2012-2020, $million
6.7 Regenerative Medicine
6.7.1 Global UCB stem cell regenerative medicine application geography market , 2012-2020, $million
6.8 Others
6.8.1 Global UCB stem cell other diseases application market , 2012-2020, $million
6.8.2 Blood Transfusion
6.8.3 Global UCB stem cell blood tranfusion application geography market 2012-2020, $million
6.8.4 Cell Based Genetics
6.8.5 Global UCB stem cell based genetics application geography market , 2012-2020, $million
CHAPTER 7 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHY
7.1 Umbilical cord blood stem cell market by geography , 2012-2020, $million
7.2 UCB stem cell market in North America
7.3 UCB stem cell market in Europe
7.4 UCB stem cell market in Asia-Pacific
7.5 UCB market in ROW
CHAPTER 8 COMPANY PROFILES
8.1 Cytori Therapeutics Inc.
8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Key Financials of Cytori Therapeutics Inc.
8.1.4 Key Strategies of Cytori Therapeutics Inc.
8.1.4.1 Primary Strategies: Approval
8.1.4.2 Secondary Strategies: Product Launch and Clinical trials
8.1.5 SWOT AnalysisofCytori Therapeutics Inc.
8.2 Advanced Cell Technology, Inc. (USA)
8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Key Financials Advanced Cell Technology, Inc. (USA)
8.2.4 Key Strategies Advanced Cell Technology, Inc. (USA)
8.2.4.1 Primary Strategies: Approval
8.2.4.2 Secondary strategies: Study Report
8.2.5 SWOT Analysis Advanced Cell Technology, Inc. (USA)
8.3 California Stem Cell
8.3.1 Company Overview
8.3.2 Company Snapshot:
8.3.3 Key Strategies California Stem Cell
8.3.3.1 Primary Strategies: Approval
8.3.3.2 Secondary Strategies: Acquisition and clinical trials
8.3.4 SWOT Analysis of California Stem Cell
8.4 Osiris Therapeutics
8.4.1 Company Overview
8.4.2 Company Snapshot:
8.4.3 Key Financials Osiris Therapeutics
8.4.4 Key Strategies Osiris Therapeutics
8.4.4.1 Primary Strategies: Approval
8.4.4.2 Secondary strategies: Clinical Trials
8.4.5 SWOT analysis of Osiris therapeutics
8.5 NeoStem Inc.
8.5.1 Company Overview
8.5.2 Company Snapshot:
8.5.3 Key Financials NeoStem Inc.
8.5.4 Key Strategies NeoStem Inc.
8.5.4.1 Primary Strategies: Clinical Trials
8.5.4.2 Secondary Strategies: Collaboration
8.5.5 SWOT AnalysisofNeoStem Inc.
8.6 Geron Corporation
8.6.1 Company Overview
8.6.2 Company Snapshot:
8.6.3 Key Financials Geron Corporation
8.6.4 Key Strategies Geron Corporation
8.6.4.1 Primary Strategies: Clinical Trials and Investment
8.6.4.2 Secondary Strategies: Collaboration
8.6.5 SWOT Analysis of Geron Corporation
8.7 Opexa Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Company Snapshot:
8.7.3 Key Strategies Opexa Therapeutics, Inc.
8.7.3.1 Primary Strategies: Approval
8.7.3.2 Secondary Strategies: Agreement
8.7.4 SWOT Analysis of Opexa Therapeutics, Inc.
8.8 Athersys, Inc.
8.8.1 Company Overview
8.8.2 Company Snapshot:
8.8.3 Key Financials of Athersys, Inc.
8.8.4 Key Strategies Athersys, Inc.
8.8.4.1 Primary Strategies: Clinical Trials
8.8.4.2 Secondary Strategies: Collaboration
8.8.5 SWOT Analysis Athersys, Inc.
8.9 Pluristem Therapeutics Inc.
8.9.1 Company Overview
8.9.2 Company Snapshot:
8.9.3 Key FinancialsPluristem Therapeutics Inc.
8.9.4 Key Strategies Pluristem Therapeutics Inc.
8.9.4.1 Primary Strategies: Approval& Clearance
8.9.4.2 Secondary Strategies: Product Launch
8.9.5 SWOT Analysis of Pluristem Therapeutics Inc.
8.10 Mesoblast Limited
8.10.1 Company Overview
8.10.2 Company Snapshot:
8.10.3 Key Financials of Mesoblast Limited
8.10.4 Key Strategies of Mesoblast Limited
8.10.4.1 Primary Strategies: Acquisition
8.10.4.2 Secondary Strategies: Approval
8.10.5 SWOT Analysis ofMesoblast Limited
1.1 Key objectives
1.2 Key benefits
1.3 Key deliverables
1.4 Key audiences
1.5 Research methodology
1.5.1 Secondary research
1.5.2 Primary research
1.5.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Umbilical cord blood stem cell market by Geography , 2012-2020, $million
CHAPTER 3 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEW
3.1 Market Description
3.2 Market definition and Scope
3.3 Awareness programs for cord blood donation
3.4 Key findings
3.4.1 Top ten factors impacting UCB stem cell market
3.4.1.1 Minimal invasive techniques of collection and transferring
3.4.1.2 Efficient extraction of cord blood
3.4.1.3 Storage service for maintaining viability
3.4.1.4 Government regulation and intervention
3.4.1.5 Ethical issues in storage and application
3.4.1.6 Cost of treatment
3.4.1.7 Availability of treatment and sample
3.4.1.8 Positive engraftment of tissue
3.4.1.9 Efficient transferring during treatment
3.4.1.10 Reimbursement and insurance issues in storage
3.4.2 Top winning strategies
3.4.3 Top Investment pockets
3.4.3.1 UCB stem cell market - by Application
3.4.3.2 UCB market- by Therapeutics
3.4.3.3 UCB market- by Storage service
3.5 Advantages of umbilical cord blood stem cells over peripheral blood stem cells
3.6 Key advantages of UCB stem cells.
3.6.1 Prompt availability
3.6.2 Ease of collection
3.6.3 More tolerance for graft failure
3.6.4 Reduce risk of Graft vs. host disease (GvHD)
3.6.5 Decreased transmission of viral disease infection
3.7 Regulatory issues, legislations and authorities Reimbursement Issues
3.7.1 Regulatory issues of UCB stem cells storage and application (U.S.)
3.7.1.1 American Academy of Pediatrics (AAP)
3.7.1.2 American society for Blood and Marrow Transplantation (ASBMT)
3.7.2 Regulatory issues concenringUCB stem cells storage and application in European countries
3.7.3 Reimbursement issues
3.8 Ethical issues of stem cell therapies and cord blood banking
3.8.1 Ethical issues regarding cord blood banking
3.8.2 Ethical issues in cord blood stem cell therapies
3.9 Umbilical cord blood stem cell collection process
3.10 UCB Stem cells Storage and collection Outsourcing
3.10.1 Stem cell storage and collection outsourcing
3.10.1.1 Criteria for outsourcing of cord blood storage
3.11 Key patents and analysis of Novel Patents
3.12 Clinical trials in UCB stem cell market
3.12.1 Phase 2 Study of stem cell Educator Therapy in Type 1 Diabetes
3.12.2 Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children
3.12.3 Longitudinal Study of Immune Mediated Disorders After AllogenicHematopoietic Cell Transplantation (HCT)
3.12.4 Evaluation of Hematopoietic and Immunologic Reconstitution after a Reduced-intensity Conditioning Regimen
3.12.5 Umbilical Cord Blood Transplant for Congenital Pediatrics Disorders
3.13 Value chain analysis of UCB stem cell market
3.14 Porter’s five forces analysis for cord blood stem cell market
3.14.1 Higher bargaining power of suppliers for getting competitive advantage
3.14.2 Lower bargaining power of buyers in terms of treatment
3.14.3 Higher degree of competition
3.14.4 Threats of new entrants increases due to novel therapies
3.14.5 Increased threats fromconventional therapies and banking substitutes
3.15 Market Dynamics of UCB stem cell market
3.15.1 Market Drivers
3.15.1.1 Minimal invasive methods
3.15.1.2 Treatment on chronic diseases
3.15.1.3 Cost effective therapy and storage
3.15.1.4 Easy extraction methods
3.15.1.5 Intact genetic structure
3.15.2 Market Restraints
3.15.2.1 Government regulations and intervention
3.15.2.2 Legal and ethical issues during collection
3.15.2.3 Availability of right type of donor
3.15.2.4 Higher cost of therapies
3.15.3 Market Opportunities
3.15.3.1 Advancement in therapeutic application
3.15.3.2 Rising funds for public storage
3.15.3.3 Increase in cost effectiveness to increase APAC market presence
CHAPTER 4 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICE
4.1 Difference between Public vs. Private UCB banks
4.1.1 Umbilical cord blood stem cell storage service market ,2012-2020, $million
4.2 Market Drivers
4.2.1 Lower cost structure
4.2.2 Immediate availability
4.2.3 Government Intervention
4.2.4 Decrease transplant complications
4.3 Market Restraints
4.3.1 Long term storage
4.3.2 Lower volume of blood
4.3.3 Operational Issues
4.3.4 Legal & Ethical Issues
4.4 Market Opportunities
4.4.1 Additional fund collection
4.4.2 Technological adoptions
4.4.3 Insurance as USP
4.4.4 Lowering healthcare costs
4.5 Public cord blood banks
4.5.1 Cost structure of public cord blood banking:
4.5.2 UCB public storage bank service market , 2012-2020, $million
4.6 Private cord blood banks
4.6.1 UCB private storage bank service market ,2012-2020, $million
CHAPTER 5 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICS
5.1 Umbilical cord blood stem cell therapeutics market , 2012-2020, $million
5.2 Market Drivers
5.2.1 Fast recovery
5.2.2 Efficient transferring of stem cells
5.2.3 Minimum invasive technique
5.2.4 Target specific
5.3 Market Restraints
5.3.1 Higher cost of treatment
5.3.2 Scarcity of donor
5.3.3 Rejection in allogenictransplantation
5.3.4 Difficulty in donor matching
5.4 Opportunities
5.4.1 Increasing flexibility
5.4.2 Improved donor policy
5.4.3 Risk management
5.5 Cancer/ Oncology diseases
5.5.1 UCB stem cell cancer therapeutics geography market , 2012-2020, $million
5.5.2 UCB stem cell cancer therapeutics market , 2012-2020, $million
5.5.3 Acute Leukemia
5.5.4 UCB stem cell Acute leukemia therapeutics market , 2012-2020,$million
5.5.5 Chronic Leukemia
5.5.6 GLOBAL UCB stem cell Chronic leukemia therapeutics market , 2012-2020, $million
5.5.7 High risk solid tumours
5.5.8 Global UCB stem cell high risk solid tumor therapeutics market , 2012-2020, $million
5.5.9 Myelodysplastic syndrome
5.5.10 Global UCB stem cell Myleodysplastic syndrome (MDS) therapeutics market , 2012-2020,$million
5.5.11 Others(chronic myelomonocyticleukemia (CMML))
5.5.12 UCB stem cell other disease therapeutics geography market , 2012-2020, $million
5.6 Diabetes
5.6.1 Global UCB stem cell diabetes therapeutics market , 2012-2020, $million
5.6.2 Global UCB stem cell diabetes therapeutics geography market , 2012-2020, $million
5.6.3 Type 1 diabetes
5.6.4 Global UCB stem cell type I diabetes therapeutics geography market, 2012-2020, $million
5.6.5 Type 2 diabetes
5.6.6 UCB stem cell Type II diabetes therapeutics geography market , 2012-2020, $million
5.6.7 Others(Gestational Diabetes Mellitus(GDM))
5.6.8 UCB stem cell Gestational Diabetes Mellitus(GDM) therapeutics geography market , 2012-2020, $million
5.7 Blood diseases
5.7.1 UCB stem cell blood diseases therapeutics market , 2012-2020, $million
5.7.2 UCB stem cell blood diseases therapeutics geography market, 2012-2020, $million
5.7.3 Aplastic Anemia
5.7.4 Global UCB stem cell Aplastic anemia therapeutics geography market 2012-2020, $million
5.7.5 Beta Thalassemia
5.7.6 Global UCB stem cell Thalassemia therapeutics geography market , 2012-2020, $million
5.7.7 Sickle Cell disease
5.7.8 Global UCB stem cell Sickle cell disease therapeutics geography market 2012-2020, $million
5.7.9 Others (Iron deficiency anemia)
5.7.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million
5.8 Immune Disorders
5.8.1 Global UCB stem cell immune disorders therapeutics market , 2012-2020, $million
5.8.2 Global UCB stem cell immune disorders therapeutics geography market , 2012-2020, $million
5.8.3 Leukocyte Adhesion Deficiency
5.8.4 Global UCB stem cell Leukocyte Adhesion deficiency therapeutics geography market , 2012-2020, $million
5.8.5 Hystiocytic disorders
5.8.6 Global UCB stem cell Hystiocytic disorders therapeutics geography market 2012-2020, $million
5.8.7 Wiskott-Aldrich
5.8.8 Global UCB stem cell Wiskott-Aldrich therapeutics geography market 2012-2020, $million
5.8.9 Others(Inflammatory Bowel Disease (IBD) and Multiple Sclerosis(MS))
5.8.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $million
5.9 Metabolic Disorders
5.9.1 Global UCB stem cell metabolic disorders therapeutics market , 2012-2020, $million
5.9.2 Global UCB stem cell metabolic disorders therapeutics geography market , 2012-2020, $million
5.9.3 Krabbe Disease
5.9.4 Global UCB stem cell Krabbe disease therapeutics geography market , 2012-2020, $million
5.9.5 Hurler Syndrome
5.9.6 Global UCB stem cell Hurler syndrome therapeutics geography market , 2012-2020, $million
5.9.7 Sanfilippo Syndrome
5.9.8 Global UCB stem cell Sanfilippo Syndrome therapeutics geography market , 2012-2020, $million
5.9.9 Others (Fabry disease)
5.9.10 Global UCB stem cell Fabry disease therapeutics geography market , 2012-2020, $million
5.10 Other diseases
5.10.1 Global UCB stem cell other disease therapeutics market 2012-2020, $million
5.10.2 Osteopetrosis
5.10.3 Global UCB stem cell Osteopetrosis disease therapeutics geography market, 2012-2020, $million
5.10.4 Hemophagoyticlymphohistiocytosis (HLH)
5.10.5 Global UCB stem cell Hemophagoytic lymphohistiocytosis therapeutics geography market , 2012-2020, $million
CHAPTER 6 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATION
6.1 Umbilical cord blood stem cell application market , 2012-2020, $million
6.2 Drivers of UCB stem cell application market
6.2.1 Auto-repair process
6.2.2 Pre-surgery management
6.2.3 Disease information
6.2.4 Positive engraftment
6.3 Restraints of UCB stem cell application market
6.3.1 Higher cost of treatment
6.3.2 Genetic variation
6.3.3 Donor Matching
6.3.4 Ethical problem
6.4 Opportunity of UCB stem cell application market
6.4.1 Cost effective regenerative medicines
6.4.2 Wound management therapies
6.4.3 Growing research institute
6.5 Stem Cell Transplant
6.5.1 Global UCB stem cell transplant application market , 2012-2020, $million
6.5.2 Autologous transplant
6.5.3 Global UCB stem cell autologous transplant applicationgeogrpahy market 2012-2020, $million
6.5.4 Allogenictransplant
6.5.5 Global UCB stem cell allogenic transplant application geography market , 2012-2020, $million
6.6 Transplant Medicine
6.6.1 Global UCB stem cell transplant medicine application geography market , 2012-2020, $million
6.7 Regenerative Medicine
6.7.1 Global UCB stem cell regenerative medicine application geography market , 2012-2020, $million
6.8 Others
6.8.1 Global UCB stem cell other diseases application market , 2012-2020, $million
6.8.2 Blood Transfusion
6.8.3 Global UCB stem cell blood tranfusion application geography market 2012-2020, $million
6.8.4 Cell Based Genetics
6.8.5 Global UCB stem cell based genetics application geography market , 2012-2020, $million
CHAPTER 7 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHY
7.1 Umbilical cord blood stem cell market by geography , 2012-2020, $million
7.2 UCB stem cell market in North America
7.3 UCB stem cell market in Europe
7.4 UCB stem cell market in Asia-Pacific
7.5 UCB market in ROW
CHAPTER 8 COMPANY PROFILES
8.1 Cytori Therapeutics Inc.
8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Key Financials of Cytori Therapeutics Inc.
8.1.4 Key Strategies of Cytori Therapeutics Inc.
8.1.4.1 Primary Strategies: Approval
8.1.4.2 Secondary Strategies: Product Launch and Clinical trials
8.1.5 SWOT AnalysisofCytori Therapeutics Inc.
8.2 Advanced Cell Technology, Inc. (USA)
8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Key Financials Advanced Cell Technology, Inc. (USA)
8.2.4 Key Strategies Advanced Cell Technology, Inc. (USA)
8.2.4.1 Primary Strategies: Approval
8.2.4.2 Secondary strategies: Study Report
8.2.5 SWOT Analysis Advanced Cell Technology, Inc. (USA)
8.3 California Stem Cell
8.3.1 Company Overview
8.3.2 Company Snapshot:
8.3.3 Key Strategies California Stem Cell
8.3.3.1 Primary Strategies: Approval
8.3.3.2 Secondary Strategies: Acquisition and clinical trials
8.3.4 SWOT Analysis of California Stem Cell
8.4 Osiris Therapeutics
8.4.1 Company Overview
8.4.2 Company Snapshot:
8.4.3 Key Financials Osiris Therapeutics
8.4.4 Key Strategies Osiris Therapeutics
8.4.4.1 Primary Strategies: Approval
8.4.4.2 Secondary strategies: Clinical Trials
8.4.5 SWOT analysis of Osiris therapeutics
8.5 NeoStem Inc.
8.5.1 Company Overview
8.5.2 Company Snapshot:
8.5.3 Key Financials NeoStem Inc.
8.5.4 Key Strategies NeoStem Inc.
8.5.4.1 Primary Strategies: Clinical Trials
8.5.4.2 Secondary Strategies: Collaboration
8.5.5 SWOT AnalysisofNeoStem Inc.
8.6 Geron Corporation
8.6.1 Company Overview
8.6.2 Company Snapshot:
8.6.3 Key Financials Geron Corporation
8.6.4 Key Strategies Geron Corporation
8.6.4.1 Primary Strategies: Clinical Trials and Investment
8.6.4.2 Secondary Strategies: Collaboration
8.6.5 SWOT Analysis of Geron Corporation
8.7 Opexa Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Company Snapshot:
8.7.3 Key Strategies Opexa Therapeutics, Inc.
8.7.3.1 Primary Strategies: Approval
8.7.3.2 Secondary Strategies: Agreement
8.7.4 SWOT Analysis of Opexa Therapeutics, Inc.
8.8 Athersys, Inc.
8.8.1 Company Overview
8.8.2 Company Snapshot:
8.8.3 Key Financials of Athersys, Inc.
8.8.4 Key Strategies Athersys, Inc.
8.8.4.1 Primary Strategies: Clinical Trials
8.8.4.2 Secondary Strategies: Collaboration
8.8.5 SWOT Analysis Athersys, Inc.
8.9 Pluristem Therapeutics Inc.
8.9.1 Company Overview
8.9.2 Company Snapshot:
8.9.3 Key FinancialsPluristem Therapeutics Inc.
8.9.4 Key Strategies Pluristem Therapeutics Inc.
8.9.4.1 Primary Strategies: Approval& Clearance
8.9.4.2 Secondary Strategies: Product Launch
8.9.5 SWOT Analysis of Pluristem Therapeutics Inc.
8.10 Mesoblast Limited
8.10.1 Company Overview
8.10.2 Company Snapshot:
8.10.3 Key Financials of Mesoblast Limited
8.10.4 Key Strategies of Mesoblast Limited
8.10.4.1 Primary Strategies: Acquisition
8.10.4.2 Secondary Strategies: Approval
8.10.5 SWOT Analysis ofMesoblast Limited
LIST OF TABLES
TABLE 1 UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 2 DIFFERENCE BETWEEN PERIPHERAL BLOOD AND CORD BLOOD
TABLE 3 CLINICAL TRIALS PHASE 2 STUDY OF STEM CELL EDUCATOR THERAPY IN TYPE 1 DIABETES
TABLE 4 UMBILICAL CORD BLOOD STEM CELL STORAGE SERVICE MARKET ,2012-2020, $MILLION
TABLE 5 PRICING STRUCTURE OF XYTEXCRYO INTERNATIONAL CORD BLOOD BANK
TABLE 6 PRICING STRUCTURE OF PARENT’S GUIDE TO CORD BLOOD FOUNDATION
TABLE 7 UCB PUBLIC STORAGE BANK SERVICE MARKET , 2012-2020, $MILLION
TABLE 8 PRICING CHART FOR DIFFERENT PRIVATE CORD BLOOD BANKS
TABLE 9 UCB PRIVATE STORAGE BANK SERVICE MARKET ,2012-2020, $MILLION
TABLE 10 NUMBER OF TRANSPLANT BY NEW YORK BLOOD CENTER (2009)
TABLE 11 EMERGING THERAPIES FROM CORD BLOOD STEM IN CHILDREN (2012)
TABLE 12 UMBILICAL CORD BLOOD STEM CELL THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 13 UCB STEM CELL CANCER THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 14 UCB STEM CELL CANCER THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 15 UCB STEM CELL ACUTE LEUKEMIA THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 16 GLOBAL UCB STEM CELL CHRONIC LEUKEMIA THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 17 GLOBAL UCB STEM CELL HIGH RISK SOLID TUMOR THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 18 GLOBAL UCB STEM CELL MYLEODYSPLASTIC SYNDROME (MDS) THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 19 UCB STEM CELL OTHER DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 20 GLOBAL UCB STEM CELL DIABETES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 21 GLOBAL UCB STEM CELL DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 22 GLOBAL UCB STEM CELL TYPE I DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 23 UCB STEM CELL TYPE II DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 24 UCB STEM CELL GESTATIONAL DIABETES MELLITUS(GDM) THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 25 UCB STEM CELL BLOOD DISEASES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 26 UCB STEM CELL BLOOD DISEASES THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 27 GLOBAL UCB STEM CELL APLASTIC ANEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 28 GLOBAL UCB STEM CELL THALASSEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 29 GLOBAL UCB STEM CELL SICKLE CELL DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 30 GLOBAL UCB STEM CELL OTHERS DIESEA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 31 GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 32 GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 33 GLOBAL UCB STEM CELL LEUKOCYTE ADHESION DEFICIENCY THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 34 GLOBAL UCB STEM CELL HYSTIOCYTIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET 2012-2020, $MILLION
TABLE 35 GLOBAL UCB STEM CELL WISKOTT-ALDRICH THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 36 GLOBAL UCB STEM CELL OTHERS.DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 37 GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 38 GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 39 GLOBAL UCB STEM CELL KRABBE DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 40 GLOBAL UCB STEM CELL HURLER SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 41 GLOBAL UCB STEM CELL SANFILIPPO SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 42 GLOBAL UCB STEM CELL FABRY DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 43 GLOBAL UCB STEM CELL OTHER DISEASE THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 44 GLOBAL UCB STEM CELL OSTEOPETROSIS DISEASE THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 45 GLOBAL UCB STEM CELL HEMOPHAGOYTIC LYMPHOHISTIOCYTOSIS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 46 UMBILICAL CORD BLOOD STEM CELL APPLICATION MARKET , 2012-2020, $MILLION
TABLE 47 GLOBAL UCB STEM CELL TRANSPLANT APPLICATION MARKET , 2012-2020, $MILLION
TABLE 48 GLOBAL UCB STEM CELL TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 49 GLOBAL UCB STEM CELL AUTOLOGOUS TRANSPLANT APPLICATIONGEOGRPAHY MARKET , 2012-2020, $MILLION
TABLE 50 GLOBAL UCB STEM CELL ALLOGENIC TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 51 GLOBAL UCB STEM CELL TRANSPLANT MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 52 GLOBAL UCB STEM CELL REGENERATIVE MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 53 GLOBAL UCB STEM CELL OTHER DISEASES APPLICATION MARKET , 2012-2020, $MILLION
TABLE 54 GLOBAL UCB STEM CELL BLOOD TRANFUSION APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 55 GLOBAL UCB STEM CELL BASED GENETICS APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 56 COMPARATIVE ANALYSIS OF MARKET BY GEOGRAPHY
TABLE 57 UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 58 CYTORI THERAPEUTICS INC(USA) COMPANY SNAPSHOT
TABLE 59 ADVANCED CELL TECHNOLOGIES INC. COMPANY SNAPSHOT
TABLE 60 CALIFORNIA STEM CELL INC. COMPANY SNAPSHOT
TABLE 61 OSIRIS THERAPEUTICS COMPANY SNAPSHOT
TABLE 62 NEOSTEM INC COMPANY SNAPSHOT
TABLE 63 GERON CORPORATION COMPANY SNAPSHOT
TABLE 64 OPEXA THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 65 ATHERSYS INC. COMPANY SNAPSHOT
TABLE 66 PLURISTEM THERAPEUTICS INC. COMPANY SNAPSHOT
TABLE 67 MESOBLAST LIMITED COMPANY SNAPSHOT
TABLE 1 UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 2 DIFFERENCE BETWEEN PERIPHERAL BLOOD AND CORD BLOOD
TABLE 3 CLINICAL TRIALS PHASE 2 STUDY OF STEM CELL EDUCATOR THERAPY IN TYPE 1 DIABETES
TABLE 4 UMBILICAL CORD BLOOD STEM CELL STORAGE SERVICE MARKET ,2012-2020, $MILLION
TABLE 5 PRICING STRUCTURE OF XYTEXCRYO INTERNATIONAL CORD BLOOD BANK
TABLE 6 PRICING STRUCTURE OF PARENT’S GUIDE TO CORD BLOOD FOUNDATION
TABLE 7 UCB PUBLIC STORAGE BANK SERVICE MARKET , 2012-2020, $MILLION
TABLE 8 PRICING CHART FOR DIFFERENT PRIVATE CORD BLOOD BANKS
TABLE 9 UCB PRIVATE STORAGE BANK SERVICE MARKET ,2012-2020, $MILLION
TABLE 10 NUMBER OF TRANSPLANT BY NEW YORK BLOOD CENTER (2009)
TABLE 11 EMERGING THERAPIES FROM CORD BLOOD STEM IN CHILDREN (2012)
TABLE 12 UMBILICAL CORD BLOOD STEM CELL THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 13 UCB STEM CELL CANCER THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 14 UCB STEM CELL CANCER THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 15 UCB STEM CELL ACUTE LEUKEMIA THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 16 GLOBAL UCB STEM CELL CHRONIC LEUKEMIA THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 17 GLOBAL UCB STEM CELL HIGH RISK SOLID TUMOR THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 18 GLOBAL UCB STEM CELL MYLEODYSPLASTIC SYNDROME (MDS) THERAPEUTICS MARKET , 2012-2020,$MILLION
TABLE 19 UCB STEM CELL OTHER DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 20 GLOBAL UCB STEM CELL DIABETES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 21 GLOBAL UCB STEM CELL DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 22 GLOBAL UCB STEM CELL TYPE I DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 23 UCB STEM CELL TYPE II DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 24 UCB STEM CELL GESTATIONAL DIABETES MELLITUS(GDM) THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 25 UCB STEM CELL BLOOD DISEASES THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 26 UCB STEM CELL BLOOD DISEASES THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 27 GLOBAL UCB STEM CELL APLASTIC ANEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 28 GLOBAL UCB STEM CELL THALASSEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 29 GLOBAL UCB STEM CELL SICKLE CELL DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 30 GLOBAL UCB STEM CELL OTHERS DIESEA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 31 GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 32 GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 33 GLOBAL UCB STEM CELL LEUKOCYTE ADHESION DEFICIENCY THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 34 GLOBAL UCB STEM CELL HYSTIOCYTIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET 2012-2020, $MILLION
TABLE 35 GLOBAL UCB STEM CELL WISKOTT-ALDRICH THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 36 GLOBAL UCB STEM CELL OTHERS.DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 37 GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 38 GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 39 GLOBAL UCB STEM CELL KRABBE DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 40 GLOBAL UCB STEM CELL HURLER SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 41 GLOBAL UCB STEM CELL SANFILIPPO SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 42 GLOBAL UCB STEM CELL FABRY DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 43 GLOBAL UCB STEM CELL OTHER DISEASE THERAPEUTICS MARKET , 2012-2020, $MILLION
TABLE 44 GLOBAL UCB STEM CELL OSTEOPETROSIS DISEASE THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
TABLE 45 GLOBAL UCB STEM CELL HEMOPHAGOYTIC LYMPHOHISTIOCYTOSIS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 46 UMBILICAL CORD BLOOD STEM CELL APPLICATION MARKET , 2012-2020, $MILLION
TABLE 47 GLOBAL UCB STEM CELL TRANSPLANT APPLICATION MARKET , 2012-2020, $MILLION
TABLE 48 GLOBAL UCB STEM CELL TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 49 GLOBAL UCB STEM CELL AUTOLOGOUS TRANSPLANT APPLICATIONGEOGRPAHY MARKET , 2012-2020, $MILLION
TABLE 50 GLOBAL UCB STEM CELL ALLOGENIC TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 51 GLOBAL UCB STEM CELL TRANSPLANT MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 52 GLOBAL UCB STEM CELL REGENERATIVE MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 53 GLOBAL UCB STEM CELL OTHER DISEASES APPLICATION MARKET , 2012-2020, $MILLION
TABLE 54 GLOBAL UCB STEM CELL BLOOD TRANFUSION APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 55 GLOBAL UCB STEM CELL BASED GENETICS APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
TABLE 56 COMPARATIVE ANALYSIS OF MARKET BY GEOGRAPHY
TABLE 57 UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
TABLE 58 CYTORI THERAPEUTICS INC(USA) COMPANY SNAPSHOT
TABLE 59 ADVANCED CELL TECHNOLOGIES INC. COMPANY SNAPSHOT
TABLE 60 CALIFORNIA STEM CELL INC. COMPANY SNAPSHOT
TABLE 61 OSIRIS THERAPEUTICS COMPANY SNAPSHOT
TABLE 62 NEOSTEM INC COMPANY SNAPSHOT
TABLE 63 GERON CORPORATION COMPANY SNAPSHOT
TABLE 64 OPEXA THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 65 ATHERSYS INC. COMPANY SNAPSHOT
TABLE 66 PLURISTEM THERAPEUTICS INC. COMPANY SNAPSHOT
TABLE 67 MESOBLAST LIMITED COMPANY SNAPSHOT
LIST OF FIGURES
FIG. 1 SUCCESS RATE FOR UCB STEM CELL TRANSPLANT BASED ON TYPE OF DONORS (2012)
FIG. 2 UCB STEM CELL MARKET DEFINITION
FIG. 3 PERCENTAGE OF WOMEN TAKING PRESCRIPTION BY PHYSICIANS (2007-2012)
FIG. 4 FACTORS IMPACTING ON UCB STEM CELL MARKET
FIG. 5 TOP WINING STRATEGIES FOR UCB STEM CELL MARKET FROM 2008-2013
FIG. 6 TOP INVESTMENT POCKETS IN UCB CORD BLOOD STEM CELL APPLICATION MARKET (2012-2020)
FIG. 7 PERCENTAGE COMPARISON OF CAGR IN THERAPEUTICS MARKET
FIG. 8 PERCENTAGE COMPARISON OF CAGR IN STORAGE SERVICE MARKET
FIG. 9 CORD BLOOD STEM CELL COLLECTION PROCEDURE
FIG. 10 KEY PATENTS FOR UCB STEM CELL FROM 2008-2013
FIG. 11 PATENT ANALYSIS FROM 2008-2013
FIG. 12 VALUE CHAIN ANALYSIS OF UCB STEM CELL MARKET
FIG. 13 PORTER FIVE FORCE MODEL FOR CORD BLOOD STEM CELL MARKET
FIG. 14 IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS IN UCB STEM CELL MARKET
FIG. 15 CORD BLOOD UNITS ON THE MATCH REGISTRY (2013)
FIG. 16 GROWTH IN DISEASE TREATED VS. CLINICAL TRIALS (2008-2012)
FIG. 17 AGE GROUP TREATED WITH CORD BLOOD STEM CELL THERAPIES
FIG. 18 TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
FIG. 19 CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
FIG. 20 SUBTYPES OF LEUKEMIA CASES IN CHILDREN WORLD-WIDE (2013)
FIG. 21 CHRONIC DISEASE BURDEN 2003-2023 ($ BILLIONS)
FIG. 22 NUMBER OF AMERICANS WITH CHRONIC DISEASES(FORECASTED)
FIG. 23 TREATMENT THERPAIES ON DIABETES, 2011
FIG. 24 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY,IN 2012(IN THOUSANDS)
FIG. 25 GLOBAL PREVALENCE OFTYPE-2 DIABETES IN 2000 &ESTIMATED PREVALENCE IN 2030
FIG. 26 SINGAPORE CORD BLOOD BANK INVENTORY AND TRANSPLANT (2005-2013)
FIG. 27 STEM CELL TRANSPLANT BY CELL SOURCE IN CHILDREN BELOW 18 YEARS
FIG. 28 IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS OF UCB STEM CELL APPLICATION MARKET
FIG. 29 EMERGING APPLICATION OF CORD BLOOD UNITS IN 2012
FIG. 30 TRANSFORMATION OF CORD BLOOD STEM CELL APPLICATION IN REGENERATIVE MEDICINE APPLICATION
FIG. 31 GROWTH RATE COMPARISON FOR UCB STEM CELLGEOGRAPHY MARKET (2013-2020)
FIG. 32 U.S. FEDRAL SPENDING -FISCAL YEAR 2012
FIG. 33 CONCENTRATION OF EUROPEAN STEM CELL THERAPY FIRMS
FIG. 34 TOTAL CELL THERAPIES BY TYPES IN EUROPEAN COUNTRIES
FIG. 35 DISEASES FACED OR IN FAMILY MEMBERS IN CHINA
FIG. 36 SWOT ANALYSIS OF CYTORI THERAPEUTICS INC.
FIG. 37 SWOT ANALYSIS OF ADVANCED CELL TECHNOLOGY, INC. (USA)
FIG. 38 SWOT ANALYSIS OF CALIFORNIA STEM CELL
FIG. 39 SWOT ANALYSIS OSIRIS THERAPEUTICS
FIG. 40 SWOT ANALYSISOFNEOSTEM INC.
FIG. 41 SWOT ANALYSISOFGERONCORPORATION
FIG. 42 SWOT ANALYSIS OF OPEXA THERAPEUTICS, INC
FIG. 43 SWOT ANALYSIS OF ATHERSYS, INC.
FIG. 44 SWOT ANALYSIS OF PLURISTEM THERAPEUTICS INC.
FIG. 45 SWOT ANALYSIS FOR MESOBLAST LIMITED
COMPANIES MENTIONED
Cytori Therapeutics Inc., Advanced Cell Technology, Inc. (USA), California Stem Cell, Osiris Therapeutics, NeoStem Inc., Geron Corporation, Opexa Therapeutics, Inc., Athersys, Inc., Pluristem Therapeutics Inc. and Mesoblast Limited
FIG. 1 SUCCESS RATE FOR UCB STEM CELL TRANSPLANT BASED ON TYPE OF DONORS (2012)
FIG. 2 UCB STEM CELL MARKET DEFINITION
FIG. 3 PERCENTAGE OF WOMEN TAKING PRESCRIPTION BY PHYSICIANS (2007-2012)
FIG. 4 FACTORS IMPACTING ON UCB STEM CELL MARKET
FIG. 5 TOP WINING STRATEGIES FOR UCB STEM CELL MARKET FROM 2008-2013
FIG. 6 TOP INVESTMENT POCKETS IN UCB CORD BLOOD STEM CELL APPLICATION MARKET (2012-2020)
FIG. 7 PERCENTAGE COMPARISON OF CAGR IN THERAPEUTICS MARKET
FIG. 8 PERCENTAGE COMPARISON OF CAGR IN STORAGE SERVICE MARKET
FIG. 9 CORD BLOOD STEM CELL COLLECTION PROCEDURE
FIG. 10 KEY PATENTS FOR UCB STEM CELL FROM 2008-2013
FIG. 11 PATENT ANALYSIS FROM 2008-2013
FIG. 12 VALUE CHAIN ANALYSIS OF UCB STEM CELL MARKET
FIG. 13 PORTER FIVE FORCE MODEL FOR CORD BLOOD STEM CELL MARKET
FIG. 14 IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS IN UCB STEM CELL MARKET
FIG. 15 CORD BLOOD UNITS ON THE MATCH REGISTRY (2013)
FIG. 16 GROWTH IN DISEASE TREATED VS. CLINICAL TRIALS (2008-2012)
FIG. 17 AGE GROUP TREATED WITH CORD BLOOD STEM CELL THERAPIES
FIG. 18 TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
FIG. 19 CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
FIG. 20 SUBTYPES OF LEUKEMIA CASES IN CHILDREN WORLD-WIDE (2013)
FIG. 21 CHRONIC DISEASE BURDEN 2003-2023 ($ BILLIONS)
FIG. 22 NUMBER OF AMERICANS WITH CHRONIC DISEASES(FORECASTED)
FIG. 23 TREATMENT THERPAIES ON DIABETES, 2011
FIG. 24 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY,IN 2012(IN THOUSANDS)
FIG. 25 GLOBAL PREVALENCE OFTYPE-2 DIABETES IN 2000 &ESTIMATED PREVALENCE IN 2030
FIG. 26 SINGAPORE CORD BLOOD BANK INVENTORY AND TRANSPLANT (2005-2013)
FIG. 27 STEM CELL TRANSPLANT BY CELL SOURCE IN CHILDREN BELOW 18 YEARS
FIG. 28 IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS OF UCB STEM CELL APPLICATION MARKET
FIG. 29 EMERGING APPLICATION OF CORD BLOOD UNITS IN 2012
FIG. 30 TRANSFORMATION OF CORD BLOOD STEM CELL APPLICATION IN REGENERATIVE MEDICINE APPLICATION
FIG. 31 GROWTH RATE COMPARISON FOR UCB STEM CELLGEOGRAPHY MARKET (2013-2020)
FIG. 32 U.S. FEDRAL SPENDING -FISCAL YEAR 2012
FIG. 33 CONCENTRATION OF EUROPEAN STEM CELL THERAPY FIRMS
FIG. 34 TOTAL CELL THERAPIES BY TYPES IN EUROPEAN COUNTRIES
FIG. 35 DISEASES FACED OR IN FAMILY MEMBERS IN CHINA
FIG. 36 SWOT ANALYSIS OF CYTORI THERAPEUTICS INC.
FIG. 37 SWOT ANALYSIS OF ADVANCED CELL TECHNOLOGY, INC. (USA)
FIG. 38 SWOT ANALYSIS OF CALIFORNIA STEM CELL
FIG. 39 SWOT ANALYSIS OSIRIS THERAPEUTICS
FIG. 40 SWOT ANALYSISOFNEOSTEM INC.
FIG. 41 SWOT ANALYSISOFGERONCORPORATION
FIG. 42 SWOT ANALYSIS OF OPEXA THERAPEUTICS, INC
FIG. 43 SWOT ANALYSIS OF ATHERSYS, INC.
FIG. 44 SWOT ANALYSIS OF PLURISTEM THERAPEUTICS INC.
FIG. 45 SWOT ANALYSIS FOR MESOBLAST LIMITED
COMPANIES MENTIONED
Cytori Therapeutics Inc., Advanced Cell Technology, Inc. (USA), California Stem Cell, Osiris Therapeutics, NeoStem Inc., Geron Corporation, Opexa Therapeutics, Inc., Athersys, Inc., Pluristem Therapeutics Inc. and Mesoblast Limited
